Last reviewed · How we verify
Intal (cromoglicic acid)
Intal (generic name: cromoglicic acid) is a Mast Cell Stabilizer drug developed by Pfizer. It is currently FDA-approved (first approved 1982) for Allergic Keratoconjunctivitis, Allergic conjunctivitis, Allergic rhinitis.
At a glance
| Generic name | cromoglicic acid |
|---|---|
| Sponsor | Pfizer |
| Drug class | Mast Cell Stabilizer |
| Target | G-protein coupled receptor 35 |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
- Allergic Keratoconjunctivitis
- Allergic conjunctivitis
- Allergic rhinitis
- Asthma
- Asthma management
- Bronchospasm Prevention
- Giant papillary conjunctivitis
- Systemic mast cell disease
- Vernal Keratitis
- Vernal conjunctivitis
- Vernal keratoconjunctivitis
Common side effects
Key clinical trials
- Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia (PHASE1,PHASE2)
- Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer (PHASE2)
- PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS (PHASE2)
- Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis
- Reverse Triple Negative Immune Resistant Breast Cancer (PHASE2)
- Novel Strategies for Reducing Burn Scar Itch (PHASE3)
- Cromoglicate in Psoriasis (PHASE2)
- Cromoglicate in Mastocytosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intal CI brief — competitive landscape report
- Intal updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Intal
What is Intal?
Intal (cromoglicic acid) is a Mast Cell Stabilizer drug developed by Pfizer, indicated for Allergic Keratoconjunctivitis, Allergic conjunctivitis, Allergic rhinitis.
What is Intal used for?
Intal is indicated for Allergic Keratoconjunctivitis, Allergic conjunctivitis, Allergic rhinitis, Asthma, Asthma management.
Who makes Intal?
Intal is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).
What is the generic name of Intal?
cromoglicic acid is the generic (nonproprietary) name of Intal.
What drug class is Intal in?
Intal belongs to the Mast Cell Stabilizer class. See all Mast Cell Stabilizer drugs at /class/mast-cell-stabilizer.
When was Intal approved?
Intal was first approved on 1982.
What development phase is Intal in?
Intal is FDA-approved (marketed).
What does Intal target?
Intal targets G-protein coupled receptor 35 and is a Mast Cell Stabilizer.
Related
- Drug class: All Mast Cell Stabilizer drugs
- Target: All drugs targeting G-protein coupled receptor 35
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Allergic Keratoconjunctivitis
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Allergic rhinitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing